Merck & Co. stock slips 1.14% to EUR 128.38 premarket

Published on 11/04/2026 at 08:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck began a Phase 3 COPD trial for OHTUVAYRE on November 3. The reference base is the Xetra close of November 3, 2026 at EUR 129.86.

Pipeline catalyst and trial expansion

Merck began the ENHANCE-3 Phase 3 trial for OHTUVAYRE in adults with COPD and a history of exacerbations.
Recruitment has started, with the study planned to enroll approximately 2,136 patients across 28 countries.
The trial's primary endpoint is the annualized rate of moderate or severe COPD exacerbations.

Merck & Co., US58933Y1055, Illustration mit AI erstellt.

Merck & Co. stock traded at EUR 128.38 on Lang & Schwarz at 08:11 CET on Wednesday, November 4, 2026, 1.14 percent below the Xetra close of Tuesday, November 3, 2026 at EUR 129.86.

Merck announced the start of ENHANCE-3, a Phase 3 randomized trial evaluating OHTUVAYRE, or ensifentrine, for preventing COPD exacerbations in adults receiving standard care. The Merck announcement said recruitment has begun in the United States.

What investors should watch next

The trial plans to enroll approximately 2,136 patients in 28 countries.
Its primary endpoint is the annualized rate of adjudicated moderate or severe COPD exacerbations over 52 weeks.
Results are intended to support discussions with regulatory authorities worldwide.

Investors can follow the real-time quote of Merck & Co. stock for subsequent trading updates.

US healthcare shares remain part of the broader S&P 500 market backdrop.

See More news and analyses on Merck & Co. stock.